Jan 29, 2025 · Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares MRNA fell 2% in ...

Jan 29, 2025 · Goldman forecast RSV vaccine revenue of $1.5 billion, which is at the lowest end of the $1.5 billion to $2.5 billion range produced by Moderna. The Goldman team also says Moderna won't be cash ...

3 days ago · Pharmaceutical giant Moderna Inc. (NASDAQ:MRNA) lost 7.28 percent of its value on Monday to end the day at $36.55 apiece as investors continued to sell off positions following Goldman Sachs ...

Jan 29, 2025 · Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to...

Jan 28, 2025 · The Goldman Sachs Group reduced their price objective on shares of Moderna from $112.00 to $99.00 and set a "buy" rating for the company in a research report on Tuesday.

Jan 29, 2025 · Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue...

Jan 29, 2025 · Goldman Sachs has turned more cautious on Moderna as the biotech struggles against strong competition from other vaccine makers. Analyst Salveen Richter downgraded …

Jan 29, 2025 · Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance represents the second in a series of negative...

Jan 29, 2025 · Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. What is the Fund Sentiment? There are 1,449 funds or institutions...

4 days ago · MRNA's current price target is $67.26. Learn why top analysts are making this stock forecast for Moderna at MarketBeat.